Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months

Sang Cheol Bae, Soo Kyung Cho, Soyoung Won, Hye Soon Lee, Sang Heon Lee, Young Mo Kang, Sang Hoon Lee, Yeon Ah Lee, Jung Yoon Choe, Won Tae Chung, Chang Hee Suh, Seung Cheol Shim, Jisoo Lee, Bo Young Yoon, Dong Wook Kim, Shin Seok Lee, Wan Hee Yoo, Jin Seok Kim, Young Ok Jung, Seong Su NahChoong Ki Lee, Gwan Gyu Song, Sung Jae Choi, Chung Il Joung, Hyein Koh, Young Joo Kim

    Research output: Contribution to journalArticlepeer-review

    4 Citations (Scopus)

    Abstract

    Aim: To determine characteristics of rheumatoid arthritis (RA) patients in Korea using disease-modifying anti-rheumatic drugs (DMARDs) for at least 6 months, and to identify factors associated with poor health-related outcomes. Method: A total of 2000 RA patients aged > 20 years, treated with DMARDs for at least 6 months, and signed informed consent, were enrolled in this non-interventional, multicenter, cross-sectional observational study from December 2012 to June 2013. Health-related quality of life (HRQoL) was measured using EuroQuol 5D (EQ-5D) and functional disability was measured using the Korean Health Assessment Questionnaire (KHAQ). Univariate and multivariate linear regression analyses were used to determine the association between patient characteristics and patient-reported outcomes (PROs). Results: Of all RA patients, 84% were female, patients with low Disease Activity Score of 28 joints erythrocyte sedimentation rate (DAS-28-ESR < 3.2) was 54%, while moderate (DAS-28-ESR 3.2–5.1) and high disease activity score (DAS-28-ESR > 5.1) were 38% and 7.6%, respectively. Mean EQ-5D index score and KHAQ score were 0.6 ± 0.28 and 0.7 ± 0.67, respectively. In multivariate analysis with both PROs, average HRQoL and functional disability score appeared to be worse in persons with older age compared to younger age (P < 0.001), and worse in females compared to males (P < 0.001). Compared to patients having lower DAS (< 3.2), those with moderate and highest DAS (3.2–5.1 and > 5.1) had worse outcome measures (P < 0.001). Conclusion: In this study, higher DAS was one of the most influential factors for poor PROs among all other factors. Therefore, we could suggest appropriate treatment approaches according to DAS along with other significantly associated factors with PROs in the early stage of RA.

    Original languageEnglish
    Pages (from-to)1001-1009
    Number of pages9
    JournalInternational journal of rheumatic diseases
    Volume21
    Issue number5
    DOIs
    Publication statusPublished - 2018 May

    Keywords

    • Disease Activity Score
    • EuroQol EQ-5D
    • Korean Health Assessment Questionnaire
    • patient-reported outcomes
    • quality of life
    • rheumatoid arthritis

    ASJC Scopus subject areas

    • Rheumatology

    Fingerprint

    Dive into the research topics of 'Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months'. Together they form a unique fingerprint.

    Cite this